(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
One SCFA called butyrate boosts GLP-1
Pea protein isolates provide functional benefits and can enhance the nutritional profile of various food and beverage products, benefiting manufacturers seeking product innovation
Saxena, A
Constipation (the fourth most commonly reported side effect) Drink lots of fluids, eight, 8-ounces glasses of water a day
PlexusDx Precision Peptide Genetic Test analyzes your GLP-1 receptor variants, FTO rs9939609, MC4R rs17782313, and GIPR rs1800437, plus 150+ additional genetic insights across 14 metabolic pathways